Combined with the homemade multispectral fluorescence imaging system, the EGFR and PD-L1 expression can be identified and quantified from preclinical OSCC tumor-bearing mouse models to clinical OSCC patients, which facilitates early cancer detection and provide guidance for anti-tumor targeted therapy, image-guided surgery, and immunotherapy of OSCC. This evidence concerns the gene EGFR and cancer.